Glyconics secures £1.5m for diabetes screening tool
Medtech firm Glyconics has secured £1.5m to fund a large-scale trial programme of its diabetes screening tool, Glyconics-SX.
Based in the UK with offices in Cambridge, Norwich and Basingstoke, the start-up raised well over its intended £850k in an Enterprise Investment Scheme (EIS) funding round ahead of a Series A round next year.
The World Health Organisation projects diabetes to be the seventh leading cause of death by 2030. Early detection is key to long-term management of the condition and increased life expectancy.
Screening currently depends on blood or urine tests which require plastic disposables with related processing, logistics and costly resources. Current methods can also produce false positives or fail to detect the disease.
Described by Glyconics as a ‘game-changing’ point-of-care diabetes tool, Glyconics-SX uses miniaturised infrared spectrometry for the early diagnosis of diabetes by detecting biomarker changes in a patient’s fingernail within seconds, and without the need for single use plastics.
Register now to continue reading
Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.
Benefits of registering
-
In-depth insights and coverage of key emerging trends
-
Unrestricted access to special reports throughout the year
-
Daily technology news delivered straight to your inbox
Experts speculate over cause of Iberian power outages
I´m sure politicians will be thumping tables and demanding answers - while Professor Bell, as reported above, says ´wait for detailed professional...